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fenofibrates (4%), diltiazem hydrochloride (3%), niacin (2%), verapamil hydrochlo-
ride (1%), fluconazole (1%), gemfibrozil glucuronide (1%), amiodarone (1%), keto-
conazole (1%), and clarithromycin (1%). The proportion of patients prescribed with
CMs that potentially interact with statins was generally higher in patients with 5
CMs.CONCLUSIONS:The majority of statin users in this study were taking5 CMs.
Statin users with 5 CMs were more likely to be female and 65 years old. Use of
CMs that potentially interact with statins is not uncommon and more prevalent in
those using 5 CMs.
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OBJECTIVES: To evaluate the proportion of patients initiating statins achieving
NCEP ATP III low-density lipoprotein cholesterol (LDL-C) goals. METHODS: Adults
18 years of age, initiating statins (atorvastatin, rosuvastatin, simvastatin, prava-
statin, fluvastatin, or lovastatin) between January 1, 2009 through September 30,
2009 with no use of the index statin 3 months prior to initiation were identified via
retrospective physician survey/chart extraction. LDL-C goal attainment was eval-
uated based on: 1) LDL-C lab values extracted from patients’ medical charts at 6
weeks, 12 weeks, 6 months, and 12 months after statin initiation, and 2) physician’s
assessment. Secondary endpoints included the proportion of patients with HDL-C
40 mg/dL (male) and50 mg/dL (female), and non-HDL-C goal within 12 months.
Subgroup analyses were conducted among 4 different populations: patients with 1)
prior CHD; 2) diabetes without CHD; 3) other CHD risk equivalents excluding dia-
betes or CHD; and 4) multiple (3) concomitant medications. RESULTS: A cohort of
869 patients was identified with mean age of 52 years, mean baseline LDL-C of 162
mg/dL, HDL-C of 40mg/dL, and non-HDL-C of 206 mg/dL. The proportions of pa-
tients achieving LDL-C goal based on lab values were 38%, 59%, 66% and 74% at 6
weeks, 12 weeks, 6 months, and 12 months, and were similar based on physician
assessment. The proportion of patients with HDL-C 40 mg/dL (male) was 68%,
50 mg/dL (female) was 44%, and 68% of patients reached non-HDL-C goal. The
proportions of patients achieving LDL-C goal in subgroup populations were 22%,
41%, 52%, 63% in patients with CHD; 17%, 39%, 45%, 55% in patients with diabetes;
20%, 34%, 52%, 60% in patients with other CHD risk equivalents; and 26%, 48%, 60%,
70% in patients with multiple concomitant therapies. CONCLUSIONS: A low per-
centage of patients achieved LDL-C goal after 1 year; particularly in patients with
diabetes and other CHD risk equivalents.
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OBJECTIVES:Understand the factors associated with failing to achieve NCEP ATP III
low-density-lipoprotein cholesterol (LDL-C) goals. METHODS: Adults 18 years of
age, initiating statins (atorvastatin, rosuvastatin, simvastatin, pravastatin, fluva-
statin, or lovastatin) between 1/1/2009 through 9/30/2009 with no use of the index
statin 3 months prior to initiation were identified via retrospective physician sur-
vey/chart extraction. Risk factors associated with failing to achieve LDL-C goal
were identified using 1) direct physician assessment and 2) logistic regression anal-
ysis. Physician assessment was reported for all patients as well as 4 subgroups
(patients with CHD, type 2 diabetes without CHD, other CHD risk equivalents ex-
cluding diabetes, and multiple [3] concomitant therapies). RESULTS: A cohort of
869 patients was identified (mean age 52 years). Twenty-four percent of patients
were unable to achieve LDL-C goal within 1 year after statin initiation. Based on
physician assessment, 45% did not achieve LDL-C goal due to poor adherence to
statin therapy, 35% for lifestyle changes, 26% for no/slow improvement on statin
therapy, and 14% for adverse events (e.g., myalgia) with statin therapy. Reasons
(poor adherence to statin therapy, lifestyle changes, no/slow improvement, and
adverse events) for not achieving LDL-C goal differed among subgroups: CHD sub-
group 36%, 38%, 26%, 14%; diabetes subgroup 32%, 24%, 32%, 21%; other CHD risk
equivalents subgroup 39%, 29%, 50%, 18%; multiple concomitant therapies sub-
group 36%, 30%, 39%, 15%. The logistic regression model indicated index statin,
older age, non-adherence to statin, having diabetes or other CHD risk equivalents,
smoking, high baseline LDL-C, and low baseline HDL-C were significantly (P0.05)
associated with failing to achieve LDL-C goals. CONCLUSIONS: This retrospective
chart review identified poor adherence to statin therapy, underlying clinical con-
ditions (diabetes or other CHD risk equivalents), adverse events such as myalgia,
smoking, baseline high LDL-C, and low HDL-C as factors associated with failure to
achieve LDL-C goals.
PCV137
THE IMPACT OF DEMENTIA ON CARE PATTERNS AFTER DISCHARGE FOR
ACUTE CORONARY SYNDROMES UNDER NATIONAL HEALTH INSURANCE
SYSTEM
Lin CF1, Hsiao FY2, Bai CH3, Gau CS2, Shen LJ2
1National Taiwan University, Taipei , Taiwan, 2National Taiwan University, Taipei, Taiwan,
3Taipei Medical University, Taipei, Taiwan
OBJECTIVES: The prevalence of dementia is growing considerately in the recent
years. Little is known about how dementia affects care patterns after discharge for
acute coronary syndromes. This study was designed to assess differences between
care patterns for ACS patients with and without dementia. METHODS: We con-
ducted a retrospective cohort study of 87298 patients hospitalized for ACS (1835
with dementia) from January 1, 2006 to December 31, 2007, based on a nationwide
population-based data under national health insurance system. Primary outcomes
were use of aspirin, beta-blocker, angiotensin-converting enzyme inhibitors (ACEI)
or angiotensin receptor blocker (ARB), statin, and clopidogrel within 365 days after
the first ACS event. Secondary outcomes were implementations of invasive proce-
dures. Age-matched cohort at 1:2 ratio (N5005) was identified to control for con-
founding variable age. Multivariate logistic regression was performed to examine
the relationships between the diagnosis of dementia in ACS patients and their care
patterns. RESULTS: ACS patients with dementia were less likely to receive aspirin
(adjusted odds ratio (OR), 0.71; 95% CI, 0.64-0.78, p0.001), beta-blocker (adjusted
OR, 0.68; 95% CI, 0.61-0.75, p0.001), ACEI or ARB (adjusted OR, 0.70; 95% CI, 0.64-
0.78, p0.001), statin (adjusted OR, 0.57; 95% CI, 0.50-0.64, p0.001), and clopidogrel
(adjusted OR, 0.84; 95% CI, 0.74-0.95, p0.007) after the first ACS event compared
with ACS patients without dementia. They were also less likely to underwent in-
vasive procedures such as percutaneous transluminal coronary angioplasty (PTCA)
(adjusted OR, 0.57; 95% CI, 0.51-0.64, p0.001), coronary artery bypass graft (CABG)
(adjusted OR, 0.31; 95% CI, 0.20-0.48, p0.001), and revascularization (adjusted OR,
0.52; 95% CI, 0.47-0.59, p0.001) during the first ACS event. Similar results were
found in the age-matched cohort. CONCLUSIONS: The presence of dementia was
associated with underutilization of evidence-based therapies in ACS patients. In-
fluence of suboptimal treatments in ACS patients with dementia should be further
evaluated.
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OBJECTIVES: New treatment modalities may improve health outcomes but are
usually associated with substantial cost and budget impact, thus limiting the num-
ber of patients that may benefit from them. An alternative is implementing a
substantially lower cost intervention to a much wider population, accepting infe-
rior per-patient outcomes. We examined whether this approach can provide better
outcomes under a pre-specified budget constraint.METHODS: We used the results
from the JUPITER trial (Justification for the Use of Statins in Prevention: An Inter-
vention Trial Evaluating Rosuvastatin) and the United-States target population as a
case study. The target population is estimated at 6,700,000 patients: women 60;
men50, with normal LDL but elevated high sensitive C Reactive Protein levels. We
built a model that can compare the outcomes on the entire intended-use popula-
tion, and compared three treatment alternatives: 1) Rosuvastatin for a limited
patient population, with the clinical effect reported in JUPITER; and 2) Lowest cost
statin for most patients, with 75% of the JUPITER effect per patient; and 3) Usual
care (do-nothing) as a baseline for cost and effectiveness. We used a budget con-
straint of $200M per year, which covers the lowest cost statin for 75% of the target
population, and used a 5-year horizon, during which a potential of 268,000 Cardio-
vascular adverse events could be prevented. RESULTS: The budget allows for 3% of
the target patient population to be treated with Rosuvastatin, which resulted in
prevention of 7229 cardiovascular events as compared to usual care. Using the
lowest-cost statin allows for 75% of the target patient population to be treated
results in preventing 118,555 cardiovascular events and is cost-saving compared to
usual care. CONCLUSIONS: Under budget constraints, using lowest-cost statins
enables a substantially larger market access to treatment, which according to our
model resulted in significantly better health outcomes for the intended-use popu-
lation.
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OBJECTIVES: To present Brazilian data on atrial fibrillation (AF) and perform a cost
analysis of events related to this disease. METHODS: AF is an important risk factor
for stroke and ischemic heart failure (HF) and death. It is estimated that in Brazil
there are around 1.5 million patients with AF and that this population is correlated
with the age pyramid. The prevalence of AF in the general population is estimated
between 0.4% and 1%, increasing substantially with age. Among the strokes 20%
are related to AF and 85% of these strokes are of ischemic origin and 15% of hem-
orrhagic origin. The stroke mortality in Brazil is 20.5 per 100,000. A panel of experts
examined the resources related to the treatment of events related to AF. The panel
was conducted through a questionnaire, where the experts listed all procedures,
tests, drugs and materials used in every event. Unit costs for drugs and material
were obtained from acquisition lists (BPS and SIMPRO magazine, respectively),
hospitalization, exam and procedure costs were extracted from a public reimburse-
ment database (SIGTAP). RESULTS: From the expert panel performed, the cost of
events were: fatal ischemic stroke (IS) 11,810BRL (7,398USD), non-fatal IS without
disability 2,812BRL (1,761USD), non-fatal IS with moderate disability 4,470BRL
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